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Key Clinical Message
Patients with inferior vena cava (IVC) filters – particularly permanent filters –
are at increased risk for recurrent deep venous thrombosis (DVT). Judicious
use of IVC filters, as well as the prompt retrieval of temporary IVC filters, sub-
stantially reduces the risk of IVC thrombosis.
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A 77-year-old Hispanic man with a history of recurrent
deep venous thromboses (DVTs), diffuse large B-cell lym-
phoma (DLBCL) in complete remission, and numerous
other medical comorbidities presented to our hematology
clinic to re-establish care for surveillance of his lym-
phoma. Approximately 5 years prior to this presentation,
he was diagnosed with a DVT of the left lower extremity
at an outside hospital. For unclear reasons, an infrarenal
inferior vena cava (IVC) filter was placed and treatment
with warfarin was initiated. The patient reported complet-
ing the therapy as prescribed.
Two years later, he was diagnosed with DLBCL and
was treated with six cycles of rituximab, cyclophos-
phamide, doxorubicin, vincristine, and prednisone (R-
CHOP) chemotherapy, which was complicated by cathe-
ter-associated superficial vein thromboses of the left basi-
lic and cephalic veins, and a DVT of the right subclavian
vein. Therapeutic low-molecular-weight heparin was initi-
ated and long-term anticoagulation was recommended.
Several months after completing chemotherapy, the
patient discontinued anticoagulation in favor of consum-
ing pomegranates after reading that they were potent
anticoagulants. During the office visit, he endorsed a 3-
week history of symptomatic swelling in his bilateral
lower extremities. On physical exam, the patient had
bilateral, asymmetric lower extremity edema, with pitting
edema extending superiorly to the level of the mid-thigh.
There was no palpable lymphadenopathy or splenome-
galy.
Doppler ultrasound of the left lower extremity revealed
extensive, occlusive thrombus extending from the left
popliteal to the common femoral vein. CT venogram
(Fig. 1A and B) demonstrated thrombosis extending from
the IVC filter inferiorly to the proximal right external iliac
vein and throughout nearly all of the visualized portions
of the left venous system. There was no evidence of lym-
phadenopathy worrisome for relapsed lymphoma. The
patient was restarted on systemic anticoagulation and
subsequently lost to follow-up.
Inferior vena cava filters are being used at an increasing
rate to prevent venous thromboembolism in a variety of
clinical scenarios [1]. In a case series of 30 patients, 29
were ≥60 years of age suggesting that IVC filter thrombo-
sis is primarily a disease of the elderly [2]. Although these
devices reduce the risk of pulmonary embolism, IVC fil-
ters increase the risk of other complications. The PREPIC
study randomized 400 patients with proximal DVTs to
treatment with systemic anticoagulation and placement of
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a permanent IVC filter versus anticoagulation alone. The
mortality rate between the groups was similar, however,
the placement of an IVC filter was associated with an
increased risk of recurrent DVT that persisted to 8 years
of follow-up [3, 4]. Inferior vena cava filter thrombosis
was observed in 26/200 patients (13%) and represented
nearly half (45.6%) of the symptomatic recurrent DVTs
reported [4]. The PREPIC2 study, which evaluated
retrievable IVC filters, demonstrated a significantly lower
rate of filter thrombosis (3/193 patients, 1.6%) that corre-
lates with filter retrieval [5].
Little is known about the circumstances under which
our patient’s IVC filter was placed and why it was not
retrieved. Although his lymphoma remained in remission,
multiple risk factors increased his risk for a recurrent
DVT [6, 7]. A multivariate analysis from the PREPIC
study showed that malignancy at study inclusion
increased the incidence of recurrent DVT. The patient’s
history of prior DVT, advanced age, and the presence of
an intravascular foreign body (IVC filter) placed him at
increased risk for recurrence.
Two guidelines, both from 2006, recommend the place-
ment of retrievable (temporary) IVC filters whenever
reversible contraindications to anticoagulation are present.
These contraindications include recent hemorrhage, sur-
gery, major trauma, etc.). Other circumstances include
embolic prophylaxis during the mechanical removal of a
thrombus, and in the setting of a massive or submassive
pulmonary embolus. In each of these cases, the filter may
be retrieved after anticoagulation is resumed. Alterna-
tively, permanent filters may be deployed in individuals
who are not anticipated to be candidates for systemic
anticoagulation. Occasionally, patients with reversible
contraindications to anticoagulation will not have their
temporary IVC filter retrieved and it will become perma-
nent. Regardless of the indication for placement,
In summary, patients with IVC filters – particularly
permanent filters – are at increased risk for recurrent
DVT. Judicious use of IVC filters, as well as prompt
retrieval of IVC filters that are intended to be temporary,
substantially reduces the risk of IVC thrombosis.
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Figure 1. Inferior vena cava (IVC) thrombosis (A) Computerized tomography (CT) venogram demonstrating thrombosis of the IVC filter extending
inferiorly (sagittal reconstruction). (B) CT venogram with extensive IVC thrombus extending from the IVC filter into the venous system of the left
lower extremity (coronal reconstruction).
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